

## Effect of *Nigella sativa* Ethanol Extract on the Nitric Oxide Content and Renal Arteriole Diameter of a Pre-eclampsia Mouse Model

Ni Made Dwi Purnamayanti<sup>1</sup> , Siti Candra Windu<sup>2</sup> , Sri Poeranto<sup>3</sup> 



**Cite this article as:** Purnamayanti NMD, Windu SC, Poeranto S. Effect of *Nigella sativa* Ethanol Extract on the Nitric Oxide Content and Renal Arteriole Diameter of a Pre-eclampsia Mouse Model. *Eurasian J Med* 2018; 50(3): 148-151.

**ORCID IDs of the authors:**  
 N.M.D.P. 0000-0002-3309-1952  
 S.C.W. 0000-0001-6361-7663  
 S.P. 0000-0002-2366-4657

<sup>1</sup>Midwifery Magister Program, Brawijaya University, Malang, East Java and Polytechnic of Health Denpasar, Bali, Indonesia

<sup>2</sup>Department of Obstetrics and Gynecology, Dr. Saiful Anwar Regional Public Hospital, Malang, East Java, Indonesia

<sup>3</sup>Laboratory of Parasitology, Brawijaya University School of Medicine, Malang, East Java, Indonesia

Received: November 21, 2017

Accepted: April 19, 2018

Correspondence to: Ni Made Dwi Purnamayanti  
 E-mail: purnamayanti.dwi80@gmail.com

DOI 10.5152/eurasianjmed.2018.17123

©Copyright 2018 by the Atatürk University School of Medicine - Available online at [www.eurasianjmed.com](http://www.eurasianjmed.com)

### ABSTRACT

**Objective:** The aim of this study was to investigate the effect of *Nigella sativa* ethanol extract on nitric oxide (NO) levels and renal arteriole diameter of a pre-eclampsia mouse model.

**Materials and Methods:** This experimental study was conducted using a post-test only control group design. Thirty BALB/c mice were divided into six groups: one negative control (normal pregnant mice), one positive control (pre-eclampsia model), and four groups of pre-eclampsia mice treated with varying doses of *N. sativa* (500 mg/kg body weight (BW)/day, 1000 mg/kg BW/day, 1500 mg/kg BW/day, and 2000 mg/kg BW/day). Ethanol extract of *N. sativa* was given for 5 days. Data were analyzed using analysis of variance.

**Results:** We detected significant differences in NO levels between the pre-eclampsia mouse model and those given the ethanol extract. The latter had NO levels of  $85.77 \pm 4.47 \mu\text{M}$  (500 mg/kg BW/day),  $189.04 \pm 6.01 \mu\text{M}$  (1000 mg/kg BW/day),  $226.56 \pm 2.13 \mu\text{M}$  (1500 mg/BW/day), and  $207.98 \pm 4.74 \mu\text{M}$  (2000 mg/kg BW/day). The mean renal arteriole diameter showed significant differences among the treatment groups with *N. sativa* doses of 1000, 1500, and 2000 mg ( $15.15 \pm 2.21 \mu\text{m}$ ,  $16.35 \pm 2.52 \mu\text{m}$ , and  $15.76 \pm 3.03 \mu\text{m}$ , respectively).

**Conclusion:** *N. sativa* ethanol extract treatment increases NO levels and enlarges renal arteriole diameter of a pre-eclampsia mouse model in a dose-dependent manner.

**Keywords:** Nitric oxide, *Nigella sativa*, pre-eclampsia, renal arteriole diameter

### Introduction

Pre-eclampsia is a disorder diagnosed by an increase in blood pressure and proteinuria at 20 weeks or more of pregnancy [1]. The ischemic placenta produces soluble factors and cell debris in the bloodstream, causing systemic inflammation, along with maternal oxidative stress. This is believed to be the key factor causing endothelial dysfunction and the major symptoms leading to pre-eclampsia [2].

Healthy endothelial cells produce balanced amounts of endothelium-derived relaxing factors (EDRFs) and endothelium-derived contracting factors to support the cardiovascular system. Nitric oxide (NO) is an EDRF that induces the relaxation of smooth muscles in blood vessels through guanylyl cyclase/cyclic guanosine monophosphate (sGC/cGMP). This smooth muscle relaxation causes the dilatation of blood vessels that suppresses vascular resistance and optimizes tissue perfusion, including that in the arterioles [3].

NO production is decreased in pre-eclampsia, which leads to vasoconstriction, increase in vascular resistance, and elevation of blood pressure [4-8]. Moreover, the vasoconstriction in the renal arterioles decreases the renal blood flow and glomerular filtration rate. This causes a decline in kidney performance and contributes to increases in systemic vascular resistance and blood pressure [9, 10].

*Nigella sativa* (black cummin) has long been used as a medication, especially in the Middle East and India. Several studies have shown that the active compounds present in *N. sativa* have anti-diabetic, anti-tumor, anti-hypercholesterolemia, anti-hypertension, anti-inflammation, and digestive protection activities [11]. In particular, thymoquinone can act as an anti-inflammatory agent by inhibiting NF- $\kappa$ B protein; it also exerts antioxidant activity [12-14].

Here we investigated the potential of *N. sativa* ethanol extract to increase NO levels as a marker of endothelial cell dysfunction. We found that it can induce the dilatation of the renal arteriole in pre-eclampsia mice model.

**Materials and Methods**

Pre-eclampsia induction was performed by injecting 0.1 mL of serum taken from severe pre-eclampsia patients on days 10 and 11 of gestation. Thirty mice were divided into six groups: a negative control group (normal pregnant mice), a positive control group (pre-eclampsia model


mice), and four treatment groups. Mice in the treatment groups for whom pre-eclampsia induction was previously performed were given *N. sativa* doses of either 500, 1000, 1500, or 2000 mg/kg BW/day. Because of being an experimental animal study, no informed consent was obtained.

*N. sativa* seed extraction was performed following published methods, with only minor modifications [15, 16]. The extract doses were based on those used by Meziti [13]. The extract was orally administered from 15 days of pregnancy until 19 days of pregnancy. Following the extract treatment, NO levels in the serum of the mice were measured using a Colorimetric Griess device (RnD Systems, Minneapolis, USA). Next, the diameter of the renal arteriole was measured using hematoxylin-eosin staining of the renal tissue. The experimental protocol was approved by Ethical Clearance from the Research Ethics Committee (Animal Care and Use Committee) of the Brawijaya University No. 567/EC/KEPK-S3/11/2015.


**Table 1.** The comparison of NO levels and renal arteriole diameter between positive and negative control groups

Variables	Negative control (Healthy mice) Mean±SD	Positive control (Pre-eclampsia mice) Mean±SD	p
NO level (µM)	218.05±3.28	70.67±4.86	0.000<0.05
Arteriole diameter (µm)	20.73±4.09	8.59±1.21	0.000<α

Note: If p<0.05, data are significantly different. If p>=0.05, data are not significantly different.  
NO: Nitric oxide



**Figure 1.** The effect of *N. sativa* ethanol extract on NO levels of pre-eclampsia mice model



**Figure 2.** The effect of *N. sativa* ethanol extract on renal arteriole diameter of pre-eclampsia mice model

**Statistical Analysis**

Statistical Package for the Social Sciences 16 for Windows (SPSS Inc.; Chicago, IL, USA) as a statistical program application was used for data analyses. One-way analysis of variance (ANOVA) and least significance difference (LSD) were used to determine the significant differences among the data for each mice group. p<0.05 was considered to be significant.

**Results**

NO levels were significantly higher in the normal pregnant mice (negative control group) than in the pre-eclampsia model. The renal arteriole diameter was also larger in the normal pregnant mice than in the pre-eclampsia model (Table 1).

One-Way ANOVA helped identify significant differences in NO levels across the six groups (p<0.001). The four *N. sativa*-treated groups had higher NO levels than the pre-eclampsia model [85.77±4.47 µm (500 mg/kg BW/day), 189.04±6.01 µm (1000 mg/kg BW/day), 226.56±2.13 µm (1500 mg/BW), and 207.98±4.74 µm (2000 mg/kg BW/day) vs. 70.67±4.86 µm (pre-eclampsia model)]. NO levels tended to increase with increasing *N. sativa* dose (Figure 1).

One-Way ANOVA helped identify significant differences in renal arteriole diameter across the six groups (p<0.001). Moreover, using LSD test, it was found that the renal arteriole diameter of the pre-eclampsia model (8.59±1.21 µm) was significantly smaller than those of mice treated with *N. sativa* ethanol extract (1000 mg/kg BW/day, 1500 mg/kg BW/day, and 2000 mg/kg BW/day (15.15±2.21 µm, 16.35±2.52 µm, and 15.76±3.03 µm respectively). These data show that *N. sativa* ethanol extract causes the renal arteriole to dilate, up to a dose of 1500 mg/BW/day (Figure 2).

## Discussion

Pre-eclampsia induction in mice can be monitored by following the progress of key symptoms, such as increase in blood pressure, proteinuria, increase in placental secretions (sEng), kidney abnormality, and renal arteriole vasoconstriction [17]. Angiotensin II type I receptor agonistic autoantibodies (ATI-AAAs) induce reactive oxygen species (ROS) production through nicotinamide adenine dinucleotide phosphate oxidase. An ATI-AA-containing serum sample was injected into pregnant mice [18, 19]. Moreover, this serum also contains higher TNF- $\alpha$  concentrations that can further induce NF- $\kappa$ B production [20, 21]. Along with ROS, NF- $\kappa$ B as the transcription factor activates HIF1- $\alpha$ , which then leads to an increase in the expression of soluble FMS-like tyrosine kinase I in the placenta [2, 23, 24]. Soluble FMS-like tyrosine kinase I is an angiogenic factor that enters the maternal bloodstream and binds vascular endothelial growth factor (VEGF). Under these conditions, VEGF levels decrease, causing endothelial cell damage due to the inability of VEGFR to bind VEGF [25]. VEGF levels are also related to the activation of endothelial nitric oxide synthase (eNOS), which induces NO synthesis [26]. Thus, the reduced VEGF levels lead to a decrease in NO synthesis [27]. Furthermore, NO easily reacts with superoxide, forming peroxynitrite, and reduces NO bioavailability [28, 29].

NO is an EDRF that induces the dilatation of smooth muscles in blood vessels. This activates the soluble guanylyl cyclase (sGC) enzyme, which catalyzes the formation of cyclic guanosine 3',5'-monophosphate (cGMP) from guanosine 5'-triphosphate [30]. Moreover, NO/sGC/cGMP acts as an intracellular signal and leads to the activation of several effector molecules, ultimately resulting in vasodilatation and vascular resistance [31]. Thus, this can account for lower NO levels and larger renal arteriole diameter detected in pre-eclampsia mice than in the control group in the present study [31-35].

We suspect that thymoquinone, which scavenges superoxide, is the principal active compound responsible for the changes in NO levels and renal arteriole diameter observed in the present study [36, 37]. Thymoquinone is also known to act as an anti-inflammation agent by inhibiting NF- $\kappa$ B in a dosage-dependent manner [13, 38-40].

Thymoquinone, as the inhibitor of NF- $\kappa$ B, causes a decrease in HIF1- $\alpha$  activation in cases of pre-eclampsia. Furthermore, thymoquinone plays an important role in sFLT-1 synthesis, which triggers VEGF to bind its receptor on endothelial cells.

This increases the activation of the eNOS cascade and NO synthesis in endothelial cells.

Previous studies have shown that *N. sativa* extract can prevent tissue damage caused by ROS. The scavenger effect of thymoquinone and its derivatives has been investigated on several ROS; and they have been shown to have a strong antioxidant activity. Thymol scavenger effect is related to singlet oxygen, while both thymoquinone and dithymoquinone have the similar activity to superoxide dismutase [14]. Therefore, *N. sativa* treatment prevents NO from interacting with superoxide so that the product peroxynitrite is prevented from causing harm to the endothelial cells. Otherwise, *N. sativa* might inhibit several different targets, including calcium channels, inositol triphosphate, and intracellular Ca<sup>2+</sup> release [41]. *N. sativa* induces smooth muscle relaxation by blocking voltage-operated Ca<sup>2+</sup> channels, which leads to the dilatation of blood vessels [42].

The main limitation of this study is that the results focused only on the effect of *N. sativa* ethanol extract on NO levels and renal arteriole diameter of a pre-eclampsia mouse model dependent on the dose that we used. Because this was an *in vivo* study, we could not find the exact underlying mechanism of how *N. sativa* ethanol extract increases NO levels and enlarges the renal arteriole diameter. Besides we did not test the chemical substances or chemical compounds contained in our extracts; thus, we could not estimate the chemical compound that played a significant role in the mechanism.

In summary, *N. sativa* ethanol extract treatment increases NO levels and enlarges the renal arteriole diameter of a pre-eclampsia mouse model in a dose-dependent manner. Furthermore, NO levels and renal arteriole diameters of pre-eclampsia mouse model (without *N. sativa* ethanol extract treatment) were less than those of other mouse groups.

**Ethics Committee Approval:** Ethics committee approval was received for this study from the Research Ethics Committee (Animal Care and Use Committee) of the Brawijaya University No. 567/EC/KEPK-S3/11/2015.

**Informed Consent:** N/A

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept – N.M.D.P.; Design – S.C.W.; Supervision – N.M.D.P., S.P.; Resources – S.C.W.; Materials – N.M.D.P., S.C.W., S.P.; Data Collection and/or Processing – S.C.W., S.P.; Analysis and/or Interpretation – N.M.D.P., S.C.W., S.P.; Literature Search – S.P.; Writing Manuscript – N.M.D.P., S.C.W., S.P.; Critical Review -N.M.D.P.

**Acknowledgements:** The authors would like to thank Biochemistry and Pharmacology Laboratory and Polytechnic of Health Denpasar for facilitating this research.

**Conflict of Interest:** Authors have no conflict of interest to declare.

**Financial Disclosure:** The authors declare that this study has received no financial support.

## References

- Duley L. The global impact of pre-eclampsia and eclampsia. *Semin Perinatol* 2009; 33: 130-7. [CrossRef]
- Eiland E, Nzerue C, Faulkner M. Preeclampsia 2012. *J Pregnancy* 2012; 2012: 586578. [CrossRef]
- Yang J, Clark JW, Bryan RM, et al. Mathematical modeling of the nitric oxide/cGMP pathway in the vascular smooth muscle cell. *Am J Physiol Heart Circ Physiol* 2005; 289: 886-97. [CrossRef]
- Aydin S, Benian A, Madazli R, et al. Plasma malondialdehyde, superoxide dismutase, sE-selectin, fibronectin, endothelin-I and nitric oxide levels in women with preeclampsia. *Eur J Obstet Gynecol Reprod Biol* 2004; 113: 21-5. [CrossRef]
- Sandrim VC, Montenegro MF, Palei AC, et al. Increased circulating cell-free hemoglobin levels reduce nitric oxide bioavailability in preeclampsia. *Free Radic Biol Med* 2010; 49: 493-500. [CrossRef]
- Ehsanipoor RM, Fortson W, Fitzmaurice LE, et al. Nitric Oxide and carbon monoxide production and metabolism in preeclampsia. *Reprod Sci* 2012; 20: 542-8. [CrossRef]
- Choi JW, Im MW, Pai SH. Nitric oxide production increases during normal pregnancy and decreases in preeclampsia. *Ann Clin Lab Sci* 2002; 32: 257-63.
- Noris M, Perico N, Remuzzi G. Mechanisms of disease: Pre-eclampsia. *Nat Clin Pract Nephrol* 2005; 1: 98-114. [CrossRef]
- Conrad KP, Davison JM. The renal circulation in normal pregnancy and preeclampsia: is there a place for relaxin? *Am J Physiol Renal Physiol* 2014; 306: F1121-35. [CrossRef]
- Ponnuchamy B, Khalil R. Cellular mediators of renal vascular dysfunction in hypertension. *Am J Physiol Regul Integr Comp Physiol* 2009; 296: R1001-18. [CrossRef]
- Leong X, Mustafa MR, Jaarin K. *Nigella sativa* and its protective role in oxidative stress and hypertension. *Evid Based Complement Altern Med* 2013; 2013: 120732. [CrossRef]
- Hajhashemi V, Ghannadi A, Jafarabadi H. Black cummin seed essential oil, as a potent analgesic and antiinflammatory drug. *Phyther Res* 2004; 18: 195-9. [CrossRef]
- Meziti A, Meziti H, Boudiaf K, et al. Polyphenolic profile and antioxidant activities of *Nigella sativa* seed extracts in vitro and in vivo. *World Acad Sci Eng Technol* 2012; 6: 24-32.
- Mansour MA, Nagi MN, El-Khatib AS, et al. Effects of thymoquinone on antioxidant enzyme activities, lipid peroxidation and DT-diaphorase in different tissues of mice: a possible mechanism of action. *Cell Biochem Funct* 2002; 20: 143-51. [CrossRef]

15. Alam M, Galav V. Anti-inflammatory effect and toxicological evaluation of thymoquinone (volatile oil of black seed) on adjuvant-induced arthritis in wistar rat. *Indian J L Sci* 2013; 2: 17-22.
16. Musa D, Dilsiz N, Gumushan H, et al. Antitumor activity of an ethanol extract of *Nigella sativa* seeds. *Cancer* 2004; 735-40.
17. Kalkunte S, Boij R, Norris W, et al. Sera from preeclampsia patients elicit symptoms of human disease in mice and provide a basis for an in vitro predictive assay. *Am J Pathol* 2010; 177: 2387-98. [\[CrossRef\]](#)
18. Zhou CC, Ahmad S, Mi T, et al. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. *Hypertension* 2008; 51: 1010-9. [\[CrossRef\]](#)
19. Dechend R, Viedt C, Müller DN, et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. *Circulation* 2003; 107: 1632-9. [\[CrossRef\]](#)
20. Mihi D, Costin N, Blaga LD, et al. Implication of tumor necrosis factor - alpha in preeclampsia. *Appl Med Inform* 2008; 23: 11-8.
21. Parameswaran N, Patial S. Tumor necrosis factor- $\alpha$  signaling in macrophages. *Crit Rev Eukaryot Gene Expr* 2010; 20: 87-103. [\[CrossRef\]](#)
22. Cindrova-Davies T, Spasic-Boskovic O, Jauniaux E, et al. Nuclear factor- $\kappa$ B, p38, and stress-activated protein kinase mitogen-activated protein kinase signaling pathways regulate proinflammatory cytokines and apoptosis in human placental explants in response to oxidative stress: effects of antioxidant vitamins. *Am J Pathol* 2007; 170: 1511-10. [\[CrossRef\]](#)
23. van Uden P, Kenneth NS, Rocha S. Regulation of hypoxia-inducible factor-1 $\alpha$  by NF- $\kappa$ B. *Biochem J* 2008; 412: 477-84. [\[CrossRef\]](#)
24. Tal R, Shaish A, Barshack I, et al. Effects of hypoxia-inducible factor-1 $\alpha$  overexpression in pregnant mice: possible implications for preeclampsia and intrauterine growth restriction. *Am J Pathol* 2010; 177: 2950-62. [\[CrossRef\]](#)
25. Karumanchi S, Epstein FH. Placental ischemia and soluble fms-like tyrosine kinase 1: cause or consequence of preeclampsia? *Kidney Int* 2007; 71: 959-61. [\[CrossRef\]](#)
26. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. *Eur Heart J* 2012; 33: 829-37. [\[CrossRef\]](#)
27. Goulopoulou S, Davidge ST. Molecular mechanisms of maternal vascular dysfunction in preeclampsia. *Trends Mol Med* 2015; 21: 88-97. [\[CrossRef\]](#)
28. Münzel T, Daiber A, Ullrich V, et al. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. *Arterioscler Thromb Vasc Biol* 2005; 25: 1551-7. [\[CrossRef\]](#)
29. Estévez AG, Jordán J. Nitric oxide and superoxide, a deadly cocktail. *Ann N Y Acad Sci* 2002; 962: 207-11. [\[CrossRef\]](#)
30. Denninger JW, Marletta MA. Guanylate cyclase and the NO/cGMP signaling pathway. *Biochim Biophys Acta* 1999; 1411: 334-50. [\[CrossRef\]](#)
31. Karumanchi SA, Maynard SE, Stillman IE, et al. Preeclampsia: a renal perspective. *Kidney Int* 2005; 67: 2101-13. [\[CrossRef\]](#)
32. Vanwijck MJ, Kublickiene K, Boer K, et al. Vascular function in preeclampsia. *Cardiovasc Res* 2000; 47: 38-48. [\[CrossRef\]](#)
33. Maynard SE, Min J, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J Clin Invest* 2003; 111: 649-58. [\[CrossRef\]](#)
34. Anumba DO, Robson SC, Boys RJ, et al. Nitric oxide activity in the peripheral vasculature during normotensive and preeclamptic pregnancy. *Am J Physiol* 1999; 277: H848-54.
35. Tsukimori K, Fukushima K, Tsushima A, et al. Generation of reactive oxygen species by neutrophils and endothelial cell injury in normal and preeclamptic pregnancies. *Hypertension* 2005; 46: 696-700. [\[CrossRef\]](#)
36. Khattab MM, Nagi MN. Thymoquinone supplementation attenuates hypertension and renal damage in nitric oxide deficient hypertensive rats. *Phytother Res* 2007; 21: 410-4. [\[CrossRef\]](#)
37. Idris-Khodja N, Schini-Kerth V. Thymoquinone improves aging-related endothelial dysfunction in the rat mesenteric artery. *Naunyn Schmiedeberg Arch Pharmacol* 2012; 385: 749-58. [\[CrossRef\]](#)
38. Dehkordi FR, Kamkhah AF. Antihypertensive effect of *Nigella sativa* seed extract in patients with mild hypertension. *Fundam Clin Pharmacol* 2008; 22: 447-52. [\[CrossRef\]](#)
39. Sethi G, Ahn KS, Aggarwal BB. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. *Mol Cancer Res* 2008; 6: 1059-70. [\[CrossRef\]](#)
40. Alkharfy KM, Ahmad A, Raish M, et al. Thymoquinone modulates nitric oxide production and improves organ dysfunction of sepsis. *Life Sci* 2015; 143: 131-8. [\[CrossRef\]](#)
41. Niazmand S, Fereidouni E, Mahmoudabady M, et al. Endothelium-independent vasorelaxant effects of hydroalcoholic extract from *Nigella sativa* seed in rat aorta: the roles of Ca<sup>2+</sup> and K<sup>+</sup> channels. *Biomed Res Int* 2014; 2014: 247054. [\[CrossRef\]](#)
42. Ghayur MN, Gilani AH, Janssen LJ. Intestinal, airway, and cardiovascular relaxant activities of thymoquinone. *Evid Based Complement Alternat Med* 2012; 2012: 305319. [\[CrossRef\]](#)